A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-30

Study Completion Date

2018-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Glibenclamide from Glibesyn 5 mg tablets (Manufactured by Medochemie LTD Cyprus) and Daonil 5 mg tablets (Sanofi-Aventis Cyprus Ltd. ) after a single oral dose administration of each to healthy adults under fasting conditions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

NCT02053753

Healthy Volunteer

COMPLETED PHASE1

Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults

NCT06153758

Healthy Participants Healthy Subjects

COMPLETED PHASE1

Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

NCT04657744

Healthy

COMPLETED PHASE1

Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition

NCT01389609

Hypertension

COMPLETED PHASE1

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions

NCT01190761

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the 90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for untransformed data of Ke, tmax and t1/2e. The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax, AUC0→t and AUC0→∞ to be within 80.00-125.00%.

A comprehensive final report will be issued upon the completion of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A Test

Test drug (Glibesyn) 1 tablet contains 5 mg Glibenclamide

Group Type EXPERIMENTAL

Glibesyn

Intervention Type DRUG

1 tablet contains 5 mg Glibenclamide

B Reference

Reference drug (Daonil) 1 tablet contains 5 mg Glibenclamide

Group Type ACTIVE_COMPARATOR

Daonil

Intervention Type DRUG

1 tablet contains 5 mg Glibenclamide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glibesyn

1 tablet contains 5 mg Glibenclamide

Intervention Type DRUG

Daonil

1 tablet contains 5 mg Glibenclamide

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glibenclamide Glibenclamide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Healthy male or female, age 18 to 55 years, inclusive. 2. Body weight within 15% of normal range according to the accepted normal values for body mass index (BMI).

3\. Medical demographics without evidence of clinically significant deviation from normal medical condition.

4\. Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.

5\. Volunteer does not have allergy to the drugs under investigation.

Exclusion Criteria

* 1\. Volunteers with known allergy to the products tested. 2. Volunteers whose values of BMI were outside the accepted normal ranges. 3. Female volunteers who were pregnant, nursing. 4. Medical demographics with evidence of clinically significant deviation from normal medical condition.

5\. Results of laboratory tests which are clinically significant. 6. Acute infection within one week preceding first study drug administration. 7. History of drug or alcohol abuse. 8. Volunteer does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.

9\. Volunteer is on a special diet (for example volunteer is vegetarian). 10. Volunteer does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.

11\. Volunteer does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.

12\. Volunteer has a history of severe diseases which have direct impact on the study.

13\. Participation in a bioequivalence study or in a clinical study within the last 6 weeks before first study drug administration.

14\. Volunteer intends to be hospitalized within 3 months after first study drug administration.

15\. Volunteers who, through completion of this study, would have donated more than 500 ml of blood in 7 days, or 750 ml of blood in 30 days, 1000 ml in 90 days, 1250 ml in 120 days, 1500 ml in 180 days, 2000 ml in 270 days, 2500 ml of blood in 1 year.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes